IL6 and COVID-19: Kan Jang® decreased blood inflammatory marker IL-6 over the recovery time in the subgroup of 86 patients with mild or moderate symptoms; however, the effect was statistically insignificant in the sample size of 140 patients, which was enriched with the 54 patients infected with a less pathogenic variant during the last wave of COVID-19 (Figure 3).